Difference between revisions of "Turner JH, et al. Cancer Biother. Radiopharm. (2003) cited as Ref 550 in DOI: 10.1038/s41392-020-0110-5 (Q9813)"
Jump to navigation
Jump to search
(Created claim: Page(s) (P105): 513-524, #quickstatements; #temporary_batch_1590074839150) |
(Created claim: Fourth Author string (P152): Claringbold PG, #quickstatements; #temporary_batch_1590155310798) |
||
| Property / Fourth Author string | |||
| + | Claringbold PG | ||
| Property / Fourth Author string: Claringbold PG / rank | |||
| + | Normal rank | ||
Revision as of 13:50, 22 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Turner JH, et al. Cancer Biother. Radiopharm. (2003) cited as Ref 550 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Turner JH
0 references
Martindale AA
0 references
Boucek J
0 references
2003
0 references
Cancer Biother. Radiopharm.
0 references
18
0 references
131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital (English)
0 references
513-524
0 references
Claringbold PG
0 references
